BY WANDILE TSHUMA 

Police in Madlambuzi, Matabeleland South Province has are a suspected mental patient, Phamani Sibanda, following a violent rampage that left five people dead and two others injured on Wednesday.

According to the police statement, Sibanda (43) allegedly attacked seven people in the village using a Mopani log, a blunt object, and an unknown sharp weapon, targeting anyone who crossed his path.

The victims of this tragic attack have been identified by their next of kin:

Elliot Khupe, 101, a male adult from Bellas Village
Butho Tshuma, 97, a female adult from Bellas Village
Constance Sibanda, 66, a female adult from Bellas Village
Tiffan Surprise Ndlovu, 6, a female juvenile from Bellas Village
Catra Matsika, 72, from Central Village

In addition to the fatalities, two other women, aged 90 and 41, sustained injuries and are currently receiving treatment at Madlambuzi Clinic and Plumtree District Hospital.

The ZRP has underscored the pressing need for community awareness regarding mental health issues. “We implore the public to promptly refer mental patients to medical institutions for treatment and to actively monitor their behavior to prevent such violent incidents,” the statement elaborated. It encouraged community members to report any concerns to the National Complaints Desk at (0242) 703631 or via WhatsApp at 0712 800197, or to approach the nearest police station.

BY PAUL SIXPENCE

ZIMBABWE became the first site for the administration of a new investigational HIV vaccine. The first doses of the IAVI C114 clinical trial were administered in late July 2025 at the Mutala Trust clinical site in Harare, CITE reports.
“This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership,” said Dr. Tariro Makadzange, clinical trial lead, Mutala Trust.

“We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.”

The development of the vaccine is a partnership that brings together Zimbabwe’s Mutala Trust, ReiThera, the Ragon Institute, International AIDS Vaccine Initiative (IAVI) and African researchers who are co-leading every phase of the trial.

In phase one of the trial, the vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1) will be administered to 120 adults between the ages of 18 and 50 years including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). Besides Zimbabwe, two other clinical trial sites are located in Cape Town and Durban, South Africa.

Trial sites were chosen on the basis of their high HIV burden and to ensure that the vaccine candidate is tested within communities affected by the epidemic.

This phase of the trial will assess the safety and ability of the vaccine candidate to provoke an immune response in the human body in persons living with HIV and those who are HIV negative.

“The IAVI C114 trial is testing a new vaccine candidate known as GRAdHIVNE1. The trial represents the first time this vaccine is being tested in humans and is aimed at assessing the safety of the vaccine and its ability to stimulate the immune system,” said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead, IAVI.

In a statement, IAVI further advised that “trial participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses.” Results of the trial are likely to be available in 2027.

In the past, several HIV vaccine trials have been conducted but none proved effective in preventing HIV acquisition. The novelity of this vaccine candidate lies in that, it uses a harmless viral vector to deliver small parts of HIV “derived from critical structural regions of HIV that are less likely to mutate” with an expected likelihood to trigger an immune response.

“GRAdHIVNE1 uses a harmless virus (a vector for the vaccine derived from a non-replicating gorilla adenovirus) to deliver small, conserved parts of HIV (called epitopes) to the body’s immune system. These targets are derived from critical structural regions of HIV that are less likely to mutate, making them good targets for killer T cells in the immune system (CD8+ T cell responses) — a type of immune defense thought to be important for long-term protection against HIV. The viral vector was selected based on its ability to stimulate this type of response. Should the vaccine be successful in stimulating the desired response, it could be tested in future trials to assess its efficacy,” Dr. Vincent Muturi-Kioi further explained.

The initiation of this clinical trial demonstrates the power of partnerships at a time when the world is witnessing funding cuts towards global public health research. The IAVIC114 clinical trial is sponsored by IAVI. The vaccine candidate, GRAdHIVNE1, was developed by ReiThera and the Ragon Institute with funding from the GatesFoundation. African researchers will be leading

SOURCE| CITE